- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04617704
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
September 21, 2021 updated by: Weijun Fu, Shanghai Changzheng Hospital
Exploratory Study to Evaluate Efficacy and Safety of GC012F Injection in Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
This is a single arm, open label, multi-center prospective study to explory the safety and efficacy of GC012F CAR-T cells in patient diagnosed with high-risk chromosomal abnormalities BCMA+ multiple myeloma(MM).
Study Overview
Detailed Description
The main aim of this study is to determin the safety and efficacy of GC012F in cytogenetic high-risk MM.
GC012F is an autologus dual chimeric antigen receptor T-cell(CAR-T) therapy that targets B-cell maturation antigen(BCMA) and CD19.
This study comprises of a screening phase(less than or equal to 28 days prior to apheresis) followed by apheresis(will occur upon enroiiment); Treatment Phase including autologus stem cell transplant on Day-1 followed by infusion of GC012F on Day0 and then post-infusion assessments from Day1 to Day 84; and a Post-treatment Phase(Day 85 and up to end of the study).
Efficacy will be explored to assessed and safety will be closely monitored during the study.
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Weijun Fu
- Phone Number: +8613816052522 +8613816052522
- Email: fuweijun2010@hotmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Shanghai ChangZheng hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of active MM as defined by any of following: a) serum M protein more than or equal to 10g/dL; b) urine M protein more than or equal to 200mg/24 h; c) involved serum free light chain more than or equal to 100mg/dL with abnormal serum kappa lambda ratio;
- Patients with clear BCMA expression(percent of BCMA positive plasma cells more than or equal to 20%) detected by flow cytometry;
- High-risk chromosomal abnormal defined as presence of del17p, and/or t(4;14) and/or t(14;16);
- Estimated life expectancy more than or equal to 3 months;
- Absolute neutrophil count more than or equal to 1*10^9/L;
- Platelet count more than or equal to 25*10^9/L;
- Absolute lymphocyte count more than or equal to 1*10^8/L;
- Liver, kidney and cardiopulmonary functions meet the following requirements: a) Total bilirubin less than or equal to 2*ULN(except for Gilbert Syndrome); ALT and AST less than or equal to 2.5*ULN, maintenance of kidney function not depend on dialysis; c)Corrected serum calcium less than or equal to 12.5 mg/dL or free ion calcium less than or equal to 6.5mg/dL(1.6mmol/L);
- Sufficient venous access for leukapheresis collection and no other contraindications to leukapheresis;
- Subjects and sexual partner with fertility are willing to use effective and reliable method of contraception for at least 1 year after CAR-T infusion;
- subjects must have signed writtern informed consent.
Exclusion Criteria:
- Accompanied by other unctrolled maligancies. Two exceptions to this criteria: Recepted radical therapy carcinoma without activity within 3 years before screening; fully treated skin non-melanoma;
- Any situations not benefit for subjects to accept or tolerated to planned therapy or understand informed consent; or any situation in which investigators believe that participation in this study is not in the subject's best intreat(eg., harm to health), or any situation that may prevent, limit or confuse the assessment;
- Convulsion or stoke within past 6 months;
- Any instability or systemic disease within 6 months prior to screening, including but not limited to congestive heart failure(New York heart association classification ≥ III), unstable angina, cerebrovascular accident, or transient cerebral ischemic, myocardial infarction, LEVF<50%(assessed by an echocardiogram or multi-door circuit scan);
- Patients have central nervous system(CNS) metastases or CNS involvement(including cranial neuropathies or mass lesions and leptomeningeal disease);
- Subjects with positive HBsAg or HBcAb positive and peripheal blood HBV-DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive; HIV antibody positive; syphilis primary screening antibody positive;
- Presence or suspicious of fungi, bacteria, viruses or other infections that are uncontrollable or requiring intravenous treatment;
- Activity of autoimmune disease (such as crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), orhistory of autoimmune disease within the last 3 years;
- Clinical evidence of dementia or changes of mental state;
- Exist of pulmonary fibrosis;
- Allergy subjects or history of severe hypersensitivity;
- Oxgen inhalation requirement to maintain adequate oxygen saturation;
- Surgery (except for local anesthesia surgery) plan 2 weeks before apheresis, during or 2 weeks after CAR-T infusion;
- Patients who are accounted to be not appropriate for this investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental:GC012F treatment
BCMA+ cytogenetic high-risk multiple myeloma patients be treated with a single dose of GC012F cells.
Total dose of (1-5)*10^5/kg cells will be administered at Day 0
|
GC012F injection is a autologous dual CAR-T targeted BCMA and CD19.
A single infusion of CAR-T cells will be administered intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of adverse events after GC012F injection
Time Frame: Minimum 2 years after GC012F infusion
|
Minimum 2 years after GC012F infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of MRD negative patients after GC012F infusion
Time Frame: Minimum 2 years after GC012F infusion
|
Minimum 2 years after GC012F infusion
|
|
ORR(PR, VGPR, CR and sCR) of patients after GC012F treatment
Time Frame: Minimum 2 years after GC012F infusion(Day0)
|
percent of subjects who achieving PR or better after GC012F infusion
|
Minimum 2 years after GC012F infusion(Day0)
|
Progression free survival after GC012F treatment
Time Frame: Minimum 2 years after GC012F infusion(Day0)
|
Minimum 2 years after GC012F infusion(Day0)
|
|
Duration of response of subjects after GC012F treatment
Time Frame: Minimum 2 years after GC012F infusion(Day0)
|
Minimum 2 years after GC012F infusion(Day0)
|
|
Overall survivalof subjects after GC012F treatment
Time Frame: Minimum 2 years after GC012F infusion(Day0)
|
Minimum 2 years after GC012F infusion(Day0)
|
|
Cytokines in serum after GC012F infusion
Time Frame: Minimum 24 weeks after GC012F infusion(Day0)
|
Minimum 24 weeks after GC012F infusion(Day0)
|
|
Subset of lymphocytes in blood after GC012F infusion
Time Frame: Minimum 2 years after GC012F infusion(Day0)
|
Minimum 2 years after GC012F infusion(Day0)
|
|
Anti-GC012F antibodies in blood after GC012F infusion
Time Frame: Minimum 2 years after GC012F infusion(Day0)
|
Minimum 2 years after GC012F infusion(Day0)
|
|
Cell counts of GC012F in blood and bone marrow(if available) after GC012F infusion
Time Frame: Minimum 2 years after GC012F infusion(Day0)
|
Minimum 2 years after GC012F infusion(Day0)
|
|
Copies of GC012F in blood and bone marrow(if available) after GC012F infusion
Time Frame: Minimum 2 years after GC012F infusion(Day0)
|
Minimum 2 years after GC012F infusion(Day0)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
December 1, 2021
Primary Completion (Anticipated)
December 31, 2021
Study Completion (Anticipated)
February 1, 2022
Study Registration Dates
First Submitted
August 20, 2020
First Submitted That Met QC Criteria
October 30, 2020
First Posted (Actual)
November 5, 2020
Study Record Updates
Last Update Posted (Actual)
September 22, 2021
Last Update Submitted That Met QC Criteria
September 21, 2021
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- GBF003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on GC012F injection
-
Shanghai Changzheng HospitalGracell Biotechnology Shanghai Co., Ltd.RecruitingMultiple MyelomaChina
-
Shanghai Changzheng HospitalGracell Biotechnology Shanghai Co., Ltd.RecruitingMultiple MyelomaChina
-
Shanghai Changzheng HospitalGracell Biotechnology Shanghai Co., Ltd.Recruiting
-
RenJi HospitalGracell Biotechnology Shanghai Co., Ltd.RecruitingCAR-T Cell TherapyChina
-
Zhejiang UniversityGracell Biotechnology Shanghai Co., Ltd.Recruiting
-
Shanghai Changzheng HospitalGracell Biotechnology Shanghai Co., Ltd.Recruiting
-
Gracell Biopharmaceuticals, Inc.RecruitingRelapsed/ Refractory Multiple MyelomaUnited States
-
Gracell Biotechnologies Ltd.Recruiting
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed